FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3001170036> ?p ?o ?g. }

• W3001170036 abstract "The lungs of most patients with cystic fibrosis (CF) eventually become chronically infected with the opportunistic pathogen Pseudomonas aeruginosa (PA). This infection is recognised as consisting of free-living bacteria (known as “planktonic bacteria”) and bacteria within aggregates known as “biofilms”. Bacteria within biofilms are more tolerant to antibiotics than their planktonic counterparts. Current CF treatment of infective exacerbations aims to eradicate or control PA infection using aggressive antibiotic regimes. Despite repeated courses of antibiotics used early after initial positive cultures, many patients become permanently infected. This chronic infection/colonisation results in progressive airways obstruction and worsening bronchiectasis. Patients colonised with PA are more unwell and die at a younger age.Work conducted by colleagues had established that low dose nitric oxide (NO) can disrupt pseudomonal biofilms in the laboratory and established a novel combination of assays to study biofilm obtained directly from CF sputa. This proof of concept study aimed to discover whether non-toxic levels of NO, administered to participants during an episode of acute infective exacerbation, could disrupt bacteria from biofilms and increase the effectiveness of antibiotic therapy.A randomised, participant and outcome-assessor blind, proof of concept study was carried out to compare treatment with nitric oxide gas during acute infection with placebo. Twelve participants with CF (aged 12 or above) were randomised to receive 5-7 days of either inhaled nitric oxide gas (10ppm) or placebo (air) in addition to standard intravenous (IV) antibiotics for a pulmonary exacerbation. The primary endpoint was the microbiological effect on proportion of bacteria in biofilms in sputum between baseline and follow-up. Secondary endpoints included laboratory and clinical parameters measured at all time-points including a number of safety measures.There was no difference between the groups in the primary outcome measure of proportion of bacteria in biofilm between baseline and follow-up. In the secondary outcomes, generalised estimating equation analysis showed a significant reduction in bacteria in biofilms in the NO group at the end of 7 days NO therapy (mean log difference between groups for measured number of >20 cell aggregates 3.49 (95%CI 0.32, 6.67; p=0.031) and for biofilm volume 4.47 (95%CI -.04, 8.98; p=0.052)). Safety measures were reassuring and other parameters (including lung function) demonstrated trends in the direction of treatment, but no other results reached significance.All results are impacted by the small number of participants and the wide variability between and within participants. There was no effect seen on bacterial biofilms at follow-up, however, the secondary microbiological outcome data shows preliminary evidence of benefit using low dose NO as adjunctive therapy during the period of treatment. Results show inhaled NO therapy is safe when administered to CF patients during a pulmonary exacerbation alongside IV antibiotic therapy. Further studies are needed to investigate whether inhaled NO, or new drugs in development (e.g. novel targeted NO donor therapies) may have any impact on PA related morbidity and mortality in CF." @default.
• W3001170036 created "2020-01-30" @default.
• W3001170036 creator A5057850598 @default.
• W3001170036 date "2016-12-01" @default.
• W3001170036 modified "2023-09-23" @default.
• W3001170036 title "The role of nitric oxide as a novel therapy to disrupt bacterial biofilms in patients with cystic fibrosis" @default.
• W3001170036 hasPublicationYear "2016" @default.
• W3001170036 type Work @default.
• W3001170036 sameAs 3001170036 @default.
• W3001170036 citedByCount "0" @default.
• W3001170036 crossrefType "dissertation" @default.
• W3001170036 hasAuthorship W3001170036A5057850598 @default.
• W3001170036 hasConcept C126322002 @default.
• W3001170036 hasConcept C142724271 @default.
• W3001170036 hasConcept C204787440 @default.
• W3001170036 hasConcept C27081682 @default.
• W3001170036 hasConcept C2776938444 @default.
• W3001170036 hasConcept C2777014857 @default.
• W3001170036 hasConcept C2777637488 @default.
• W3001170036 hasConcept C2777714996 @default.
• W3001170036 hasConcept C2779379686 @default.
• W3001170036 hasConcept C501593827 @default.
• W3001170036 hasConcept C519581460 @default.
• W3001170036 hasConcept C523546767 @default.
• W3001170036 hasConcept C54355233 @default.
• W3001170036 hasConcept C58123911 @default.
• W3001170036 hasConcept C71924100 @default.
• W3001170036 hasConcept C86803240 @default.
• W3001170036 hasConcept C89423630 @default.
• W3001170036 hasConceptScore W3001170036C126322002 @default.
• W3001170036 hasConceptScore W3001170036C142724271 @default.
• W3001170036 hasConceptScore W3001170036C204787440 @default.
• W3001170036 hasConceptScore W3001170036C27081682 @default.
• W3001170036 hasConceptScore W3001170036C2776938444 @default.
• W3001170036 hasConceptScore W3001170036C2777014857 @default.
• W3001170036 hasConceptScore W3001170036C2777637488 @default.
• W3001170036 hasConceptScore W3001170036C2777714996 @default.
• W3001170036 hasConceptScore W3001170036C2779379686 @default.
• W3001170036 hasConceptScore W3001170036C501593827 @default.
• W3001170036 hasConceptScore W3001170036C519581460 @default.
• W3001170036 hasConceptScore W3001170036C523546767 @default.
• W3001170036 hasConceptScore W3001170036C54355233 @default.
• W3001170036 hasConceptScore W3001170036C58123911 @default.
• W3001170036 hasConceptScore W3001170036C71924100 @default.
• W3001170036 hasConceptScore W3001170036C86803240 @default.
• W3001170036 hasConceptScore W3001170036C89423630 @default.
• W3001170036 hasLocation W30011700361 @default.
• W3001170036 hasOpenAccess W3001170036 @default.
• W3001170036 hasPrimaryLocation W30011700361 @default.
• W3001170036 hasRelatedWork W1848436158 @default.
• W3001170036 hasRelatedWork W1971517643 @default.
• W3001170036 hasRelatedWork W1986683703 @default.
• W3001170036 hasRelatedWork W2036276557 @default.
• W3001170036 hasRelatedWork W2062685987 @default.
• W3001170036 hasRelatedWork W2100080752 @default.
• W3001170036 hasRelatedWork W2114243674 @default.
• W3001170036 hasRelatedWork W2115024536 @default.
• W3001170036 hasRelatedWork W2118796703 @default.
• W3001170036 hasRelatedWork W2143694083 @default.
• W3001170036 hasRelatedWork W2161605184 @default.
• W3001170036 hasRelatedWork W2404079246 @default.
• W3001170036 hasRelatedWork W2421041494 @default.
• W3001170036 hasRelatedWork W2488072735 @default.
• W3001170036 hasRelatedWork W2967959549 @default.
• W3001170036 hasRelatedWork W3080828326 @default.
• W3001170036 hasRelatedWork W3102928926 @default.
• W3001170036 hasRelatedWork W3166460631 @default.
• W3001170036 hasRelatedWork W17619862 @default.
• W3001170036 hasRelatedWork W2519212332 @default.
• W3001170036 isParatext "false" @default.
• W3001170036 isRetracted "false" @default.
• W3001170036 magId "3001170036" @default.
• W3001170036 workType "dissertation" @default.